FORMULATION DEVELOPMENT AND EVALUATION OF IMMEDIATE RELEASE BILAYER TABLETS OF TELMISERTAN AND HYDROCHLOROTHIAZIDE

A low - dose combination of two different agents reduces the dose related risk; the addition of one agent may counter act some deleterious effects of the other. Using low dosage of two different ag ents minimizes the clinical and metabolic effects that occur with maximal dosage of individual component of the combined tablet and thus dosage of the si ngle component can be reduced. The primary objective of formulation development was to develop a stable , essentially similar, robust and bioequivalent formulation of Telmisartan and HCTZ combination for synergistic effect which complies with the Reference product.